The hybrid receptor may be a potential therapeutic target for PF although there are several challenges associated with developing IGF1R/IR inhibitors, such as ensuring specific inhibition of the IGF1R/IR hybrid over the IR and IGF1R homodimers [87]. The gene discussed is INSR; the disease is pemphigus foliaceus.